Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Translational research in neurology and neuroscience 2010: multiple sclerosis.

Stüve O, Kieseier BC, Hemmer B, Hartung HP, Awad A, Frohman EM, Greenberg BM, Racke MK, Zamvil SS, Phillips JT, Gold R, Chan A, Zettl U, Milo R, Marder E, Khan O, Eagar TN.

Arch Neurol. 2010 Nov;67(11):1307-15. doi: 10.1001/archneurol.2010.158. Epub 2010 Jul 12. Review.

2.

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

Steinman L, Zamvil SS.

Trends Immunol. 2005 Nov;26(11):565-71. Epub 2005 Sep 8. Review.

PMID:
16153891
3.

Treatment of multiple sclerosis: role of natalizumab.

Comi G.

Neurol Sci. 2009 Oct;30 Suppl 2:S155-8. doi: 10.1007/s10072-009-0147-2. Review.

PMID:
19882365
4.

Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.

Pittock SJ, Rodriguez M.

Curr Top Microbiol Immunol. 2008;318:1-17. Review.

PMID:
18219812
5.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

6.

[Current treatment of multiple sclerosis].

Csépány T.

Lege Artis Med. 2011 Feb;21(2):97-104. Review. Hungarian.

PMID:
21710707
7.

Treating multiple sclerosis with natalizumab.

Iaffaldano P, Lucchese G, Trojano M.

Expert Rev Neurother. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. Review.

PMID:
22091593
8.

Monoclonal antibodies in the treatment of multiple sclerosis.

Di Pauli F, Berger T, Reindl M.

Curr Med Chem. 2009;16(36):4858-68. Review.

PMID:
19929782
9.

The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Robinson AP, Harp CT, Noronha A, Miller SD.

Handb Clin Neurol. 2014;122:173-89. doi: 10.1016/B978-0-444-52001-2.00008-X. Review.

10.
11.

Spotlight on statins.

Weber MS, Stuve O, Neuhaus O, Hartung HP, Zamvil SS.

Int MS J. 2007 Sep;14(3):93-7. Review.

PMID:
18028833
12.

New and emerging treatment options for multiple sclerosis.

Polman CH, Uitdehaag BM.

Lancet Neurol. 2003 Sep;2(9):563-6. Review.

PMID:
12941579
13.

[Monoclonal antibodies for the treatment of multiple sclerosis].

Sánchez-Seco VG, Casanova Peño I, Arroyo González R.

Med Clin (Barc). 2014 Dec;143 Suppl 3:30-4. doi: 10.1016/S0025-7753(15)30007-5. Review. Spanish.

PMID:
25732947
14.

Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.

Aharoni R.

J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. Review.

PMID:
24934599
15.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
16.

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Racke MK, Lovett-Racke AE.

J Immunol. 2011 Feb 15;186(4):1887-90. doi: 10.4049/jimmunol.1090138. Review.

17.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
18.

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H.

Neurology. 2012 Sep 11;79(11):1130-5. doi: 10.1212/WNL.0b013e3182698c64. Epub 2012 Aug 29. Review.

19.

Drug insight: using monoclonal antibodies to treat multiple sclerosis.

Hohlfeld R, Wekerle H.

Nat Clin Pract Neurol. 2005 Nov;1(1):34-44. Review.

PMID:
16932490
20.

Is T-bet a potential therapeutic target in multiple sclerosis?

Racke MK, Yang Y, Lovett-Racke AE.

J Interferon Cytokine Res. 2014 Aug;34(8):623-32. doi: 10.1089/jir.2014.0020. Review.

PMID:
25084179

Supplemental Content

Support Center